We have a strategic working relationship with multiple contract manufacturers.
Currently, the majority of our products are produced by third party powder and
capsule manufacturing facilities located in Tennessee, New York, Utah and our
subsidiary, BioZone, in California. Certain of our vendors supply in excess of
10% of our products. In particular, one of our third-party suppliers, Capstone,
was responsible for 59% of our manufacturing spend in 2015. We have undertaken
an evaluation of our agreements with Capstone, and at this time cannot anticipate
whether Capstone will continue to be a principal vendor to us.
Musclepharm's Comment on Supply Chain
We have a strategic working relationship with multiple contract manufacturers.
Currently, the majority of our products are produced by third party powder and
capsule manufacturing facilities located in Tennessee, New York, Utah and our
subsidiary, BioZone, in California. Certain of our vendors supply in excess of
10% of our products. In particular, one of our third-party suppliers, Capstone,
was responsible for 59% of our manufacturing spend in 2015. We have undertaken
an evaluation of our agreements with Capstone, and at this time cannot anticipate
whether Capstone will continue to be a principal vendor to us.
Sources:
Musclepharm Corporation's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Musclepharm Corporation’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
